Literature DB >> 23520325

MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?

Catherine Thieblemont1, Josette Brière.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23520325     DOI： 10.1182/blood-2013-01-480392

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

1.  Lymphomatous orbital infiltration and vision loss in diffuse large B-cell lymphoma.

Authors:  Seongseok Yun; Jocelyn Ko; Nicole D Vincelette; Faiz Anwer
Journal:  BMJ Case Rep       Date:  2014-05-28

2.  BCL-W has a fundamental role in B cell survival and lymphomagenesis.

Authors:  Clare M Adams; Annette S Kim; Ramkrishna Mitra; John K Choi; Jerald Z Gong; Christine M Eischen
Journal:  J Clin Invest       Date:  2017-01-17       Impact factor: 14.808

3.  BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer.

Authors:  Yi-Qin Wang; Mi-Die Xu; Wei-Wei Weng; Ping Wei; Yu-Si Yang; Xiang Du
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

4.  The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.

Authors:  S Agarwal; J U Kazi; S Mohlin; S Påhlman; L Rönnstrand
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

5.  Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.

Authors:  Clare M Adams; Ramkrishna Mitra; Jerald Z Gong; Christine M Eischen
Journal:  Clin Cancer Res       Date:  2017-08-29       Impact factor: 12.531

6.  Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Authors:  Zijun Y Xu-Monette; Bouthaina S Dabaja; Xiaoxiao Wang; Meifeng Tu; Ganiraju C Manyam; Alexander Tzankov; Yi Xia; Li Zhang; Ruifang Sun; Carlo Visco; Karen Dybkaer; Lihui Yin; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Ben M Parsons; Xiaoying Zhao; Jane N Winter; Miguel A Piris; Timothy J McDonnell; Roberto N Miranda; Yong Li; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2015-11-06       Impact factor: 7.842

7.  A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.

Authors:  Franck Morschhauser; Pierre Feugier; Ian W Flinn; Robin Gasiorowski; Richard Greil; Árpád Illés; Nathalie A Johnson; Jean-François Larouche; Pieternella J Lugtenburg; Caterina Patti; Gilles A Salles; Marek Trněný; Sven de Vos; Farheen Mir; Divya Samineni; Su Y Kim; Yanwen Jiang; Elizabeth Punnoose; Arijit Sinha; Emma Clark; Nathalie Spielewoy; Kathryn Humphrey; Alexandra Bazeos; Andrew D Zelenetz
Journal:  Blood       Date:  2021-02-04       Impact factor: 25.476

8.  HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.

Authors:  Danielle P Johnson; Gabriella S Spitz; Shweta Tharkar; Steven N Quayle; Jeffrey R Shearstone; Simon Jones; Maria E McDowell; Hannah Wellman; Jessica K Tyler; Bradley R Cairns; Mahesh B Chandrasekharan; Srividya Bhaskara
Journal:  Oncotarget       Date:  2015-03-10

9.  The copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphoma.

Authors:  Kristy Lee; Matthew R Hart; Margaret M Briehl; Andrew P Mazar; Margaret E Tome
Journal:  Int J Oncol       Date:  2014-04-23       Impact factor: 5.650

10.  MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.

Authors:  Ting-Xun Lu; Lei Fan; Li Wang; Jia-Zhu Wu; Kou-Rong Miao; Jin-Hua Liang; Qi-Xing Gong; Zhen Wang; Ken H Young; Wei Xu; Zhi-Hong Zhang; Jian-Yong Li
Journal:  Oncotarget       Date:  2015-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.